Role of the integrin-linked kinase/TGF-β/SMAD pathway in sitagliptin-mediated cardioprotective effects in a rat model of diabetic cardiomyopathy

Diabetic cardiomyopathy is a known complication of diabetes mellitus. Herein, we aimed to determine whether glycemic control mediated by sitagliptin, a dipeptidyl peptidase-4 inhibitor, can ameliorate diabetic myocardial abnormalities by modulating TGF-β signaling via the SMAD and integrin-linked ki...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacy and pharmacology 2024-01, Vol.76 (1), p.64-73
Main Authors: Bin Dayel, Anfal F, Alonazi, Asma S, Alrasheed, Nawal M, Alamin, Maha A, Sarawi, Wedad S, Alharbi, Abeer O, Alabbad, Nahla'a A, Albuaijan, Danah A, Alassiri, Dareen N, Aljarbua, Alanoud F, Almusaytir, Fatimah K, Alrasheed, Nouf M
Format: Article
Language:English
Subjects:
Animals
Collagen
Diabetes Mellitus, Experimental - complications
Diabetes Mellitus, Experimental - drug therapy
Diabetes Mellitus, Experimental - metabolism
Diabetic Cardiomyopathies - drug therapy
Diabetic Cardiomyopathies - prevention & control
Male
Matrix Metalloproteinase 9
Rats
Rats, Wistar
Sitagliptin Phosphate - pharmacology
Sitagliptin Phosphate - therapeutic use
Transforming Growth Factor beta
Tumor Necrosis Factor-alpha
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetic cardiomyopathy is a known complication of diabetes mellitus. Herein, we aimed to determine whether glycemic control mediated by sitagliptin, a dipeptidyl peptidase-4 inhibitor, can ameliorate diabetic myocardial abnormalities by modulating TGF-β signaling via the SMAD and integrin-linked kinase (ILK) pathways. Four groups of male Wistar albino rats were used, with six rats in each group. Two nondiabetic and two diabetic (produced by a single intraperitoneal dose of streptozotocin (55 mg/kg)) groups were administered either normal saline or sitagliptin (100 mg/kg) orally for 6 weeks. Subsequently, HW/BW ratios and cardiac enzymes were assessed, along with a histological examination of cardiac tissues. Levels of TGF-β, collagen I, p-SMAD2/3, TNF-α, MMP-9, and ILK were detected. Compared with the diabetic control group, sitagliptin-treated diabetic rats exhibited considerably reduced HW/BW ratios and troponin I and creatine kinase-MB levels, with improvements in histopathological changes in cardiac tissues. TGF-β, collagen I, p-SMAD2/3, TNF-α, and MMP-9 levels were significantly decreased in the sitagliptin-treated diabetic group, whereas ILK was elevated following sitagliptin treatment. Sitagliptin could afford cardioprotective effects for the first time by altering ILK-associated TGF-β/SMAD signaling pathways. Thus, sitagliptin may be a promising therapeutic target for the prevention of diabetic cardiomyopathy.
ISSN:0022-3573
2042-7158
DOI:10.1093/jpp/rgad111